Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization
Fig 5
In silico clinical trial predicts improved outcomes for both probabilistic dosing strategies and maintenance therapy versus standard combination therapy.
Kaplan-Meier curves for Arm 1: patients receiving Standard Combination Therapy (dotted turquoise line), Arm 2: Maintenance Treatment (solid light blue line), Arm 3: Probabilistic dosing regimen determined through the in silico clinical trial (dashed dark blue line).